WeLeader Biomedical , Ltd. Overview
Get informed when a big investor buys or sells
+ Follow20.76%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
WeLeader Biomedical , Ltd. posts a ROE of 20.76%. That is above the sector sector average of 11.64%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
For its sector stocks, a ROE near 11.64% is typical. WeLeader Biomedical , Ltd.'s 20.76% is higher that level. That is roughly 78.4% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
WeLeader Biomedical , Ltd.'s ROE moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is 20.76%; use YoY and peer views to separate noise from signal.
Context for 7713.TWO's ROE usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 11.64%), and (3) consistency with growth and profitability. This page covers the first two; WeLeader Biomedical , Ltd.'s other metric pages and overview cover the third.
